Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease / 临床肝胆病杂志

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease, and its prevalence rate is increasing year by year. Insulin resistance and oxidative stress are the main pathogeneses of NAFLD, and there are still no effective drugs for the treatment of this disease. Insulin resistance is also a main pathogenesis of type 2 diabetes, and people with type 2 diabetes have a higher prevalence rate of NAFLD than those without diabetes. Liraglutide is a human glucagon-like peptide-1 analogue and can improve insulin resistance, and more and more studies have found that liraglutide has a certain therapeutic effect in patients with type 2 diabetes and NAFLD, while related mechanisms have not been fully clarified. This article reviews the therapeutic effect and related mechanisms of liraglutide in the treatment of type 2 diabetes and NAFLD.